ElectroNic Hydroxyurea AdhereNCE: A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease

Completed · Not applicable

Conditions studied: Sickle Cell Disease

In brief

HU is an FDA approved medication for the treatment of SCD. Many studies have shown that HU can reduce SCD related symptoms, but only 50% of patients take it as often as they should. This limits how much HU can help reduce SCD symptoms. Researchers are interested to see if electronic directly observed therapy (Mobile DOT), a program that uses cell phone reminder messages, videos, feedback messages, and incentives will help patients with SCD take HU as prescribed.

Key facts

Study ID

NCT02578017

Run by

Nationwide Children's Hospital

People needed

71

Starts

2014-07-01

Expected to finish

2019-06-01

Last updated by the study team

2019-07-10

Who can join

Age: any, up to 19. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Sickle Cell Disease (SCD), any genotype
• Prescribed HU for at least the previous 6 months
• Plans to receive SCD-related care at Nationwide Children's Hospital for the study duration
• For participants ≥18 years: participant must have access to a smart-phone or computer capable of recording and submitting videos to Mobile DOT
• For participants <18 years: consenting adult must have access to a smart-phone or computer capable of recording and submitting videos to Mobile DOT AND agrees to enter into a mutual agreement to participate in the daily medication administration routine
• Patient and/or consenting adult must speak English
• Access to a working phone (smart phone or landline)

You may not qualify if…

• Current chronic transfusion therapy or apheresis

Where it is running

• Nationwide Children's Hospital — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.